Novartis (NVS) to Release Earnings on Friday

Novartis (NYSE:NVS) is anticipated to release its earnings data before the market opens on Friday, January 31st. Analysts expect Novartis to post earnings of $1.80 per share and revenue of $12,855,300.00 billion for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The firm had revenue of $12.82 billion during the quarter, compared to the consensus estimate of $12.62 billion. During the same period in the previous year, the firm posted $1.74 earnings per share. On average, analysts expect Novartis to post $8 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Novartis Trading Up 1.9 %

NVS opened at $100.00 on Friday. Novartis has a 1-year low of $92.35 and a 1-year high of $120.92. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 0.55. The company has a market cap of $204.40 billion, a P/E ratio of 11.61, a price-to-earnings-growth ratio of 1.44 and a beta of 0.57. The company has a fifty day moving average price of $100.22 and a two-hundred day moving average price of $108.81.

Analysts Set New Price Targets

NVS has been the subject of several research analyst reports. BMO Capital Markets lifted their price target on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research note on Wednesday, October 30th. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. Finally, HSBC cut shares of Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Two equities research analysts have rated the stock with a sell rating and six have assigned a hold rating to the stock. According to data from MarketBeat.com, Novartis currently has an average rating of “Hold” and an average price target of $123.38.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.